A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Victor Sandor, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Moncton, New Brunswick, Canada
- Facility name not stated
Windsor, Ontario, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Québec, Canada
- Facility name not stated
Hot Springs, Arkansas, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Clinton, Minnesota, United States
- Facility name not stated
Fridley, Minnesota, United States
- Facility name not stated
Rochester, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2012
- Primary completion
- 31 Jan 2013
- Completion
- 28 Feb 2013
- Last update posted
- 12 Mar 2019
- Registered enrollment
- 50
- Registry id
- NCT01634087
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.